II. Indications
- Fourth line agent in symptomatic chronic Heart Failure with Reduced Ejection Fraction (<45%)
- Vericiguat is marketed as adjunct to triple therapy (ACE/ARB, Beta Blocker, Aldosterone Antagonist)
III. Preparations
- Verquvo (Vericiguat)
- First agent in class (released in 2020)
- Start 2.5 mg orally once daily with food
- May double dose every 2 weeks, until target dose 10 mg reached, as tolerated
IV. Mechanism
- Vasodilation and smoth Muscle relaxation via nitric oxide path and stimulation of soluble guanylate cyclase
V. Adverse effects
- Symptomatic Hypotension
VI. Drug Interactions
- PDE5 Inhibitors (e.g. Viagra)
VII. Efficacy
- Reduces hospitalization and cardiovascular death rates (but at NNT 33 at >$600/month in 2022)
Images: Related links to external sites (from Bing)
Related Studies
| verquvo (on 9/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| VERQUVO 10 MG TABLET | $19.67 each | |
| VERQUVO 2.5 MG TABLET | $19.84 each | |
| VERQUVO 5 MG TABLET | $19.66 each | |